Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Updated . What changed?
Praxis Precision Medicines, Inc is a biotechnology business based in the US. Praxis Precision Medicines shares (PRAX) are listed on the NASDAQ and all prices are listed in US Dollars. Praxis Precision Medicines employs 50 staff and has a market cap (total outstanding shares value) of USD$1.4 billion.
|52-week range||USD$19 - USD$60.9505|
|50-day moving average||USD$52.1221|
|200-day moving average||USD$44.9354|
|Wall St. target price||USD$65.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1.4 billion|
TTM: trailing 12 months
There are currently 892,701 Praxis Precision Medicines shares held short by investors – that's known as Praxis Precision Medicines's "short interest". This figure is 35.5% down from 1.4 million last month.
There are a few different ways that this level of interest in shorting Praxis Precision Medicines shares can be evaluated.
Praxis Precision Medicines's "short interest ratio" (SIR) is the quantity of Praxis Precision Medicines shares currently shorted divided by the average quantity of Praxis Precision Medicines shares traded daily (recently around 102022.97142857). Praxis Precision Medicines's SIR currently stands at 8.75. In other words for every 100,000 Praxis Precision Medicines shares traded daily on the market, roughly 8750 shares are currently held short.
To gain some more context, you can compare Praxis Precision Medicines's short interest ratio against those of similar companies.
However Praxis Precision Medicines's short interest can also be evaluated against the total number of Praxis Precision Medicines shares, or, against the total number of tradable Praxis Precision Medicines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Praxis Precision Medicines's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Praxis Precision Medicines shares in existence, roughly 20 shares are currently held short) or 0.0336% of the tradable shares (for every 100,000 tradable Praxis Precision Medicines shares, roughly 34 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Praxis Precision Medicines.
Find out more about how you can short Praxis Precision Medicines stock.
We're not expecting Praxis Precision Medicines to pay a dividend over the next 12 months.
You may also wish to consider:
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.